Editorial · 26 Mar 2021
OpinionPublished 25 Jul 2021
Note on Biosimilar
Keywords
Subjects
Pharmaceutical SciencesSimilar by topic
Opinion · 30 Jun 2025
Clinical and Pharmacokinetic Equivalence of a Biosimilar Adalimumab in Rheumatoid Arthritis Patients: A Phase III Trial
Short communication · 8 Aug 2022
Adalimumab Biosimilar Adalimumab-adbm and Reference Product Population Pharmacokinetics in Healthy Persons and Patients with Rheumatoid Arthritis to Determine Pharmacokinetic Similarities
Conference abstract · 15 Apr 2019
Biosimilar assessment: Quantitation of antibody variants and pharmacokinetic studies using peptide mapping LCand#45;MS analysis
Conference abstract · 15 Apr 2019
Biosimilar assessment: Quantitation of antibody variants and pharmacokinetic studies using peptide mapping LC-MS analysis
More from this journal
The newest in Journal of Formulation Science & Bioavailability.
Opinion · 29 Nov 2025
AI Revolutionizing Pharmaceutical Formulation: Efficiency, Safety, Innovation
Opinion · 29 Nov 2025
Advanced Nanodrug Delivery for Poorly Soluble Drugs
Commentary · 29 Nov 2025
Oral Biopharmaceutical Delivery: Advanced Formulation Solutions
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Formulation Science & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Osama Halabi”

